CME Information
A CME-certified enduring webcast focusing on highlights from the 75th American College of Gastroenterology 2007 Annual Scientific Meeting.
Target audience
This CME-certified activity has been developed for gastroenterologists who have an interest in optimizing the management of patients with Crohn's disease.
Learning objectives:
Upon completion of this activity participants should be able to:
- Summarize the latest concepts in the diagnosis, evaluation and treatment of patients with Crohn’s disease
- Discuss how recent data presented at ACG 2007 will advance current clinical practice in the management of Crohn’s disease
- Explain how to integrate the best available evidence with expert clinical opinion to achieve a new level of best practice.
Syllabus disclosure statement
In direct response to the September 2004 Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during this CME/CE activity.
The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA approved uses of pharmaceuticals, medical equipment, prostheses, etc. will be included in their presentation.
| Faculty Name | Company | Relationship |
| Stephen B. Hanauer | Abbott Laboratories, Amgen, Asahi, Astra Zeneca, Bristol Myers Squibb, Centocor, Inc., ChemoCentryx, Elan Pharmaceuticals, Inc., Ferring, Genentech Inc., GSK, Millenium Pharmaceuticals Inc., Novartis, Otsuka, Protein Design Labs, Procter and Gamble, Prometheus Laboratories, Inc., Salix Pharmaceuticals Inc., Shire Pharmaceuticals, Solvay, Targacept, Teva, Therakos, UCB, Inc. | Consultant |
| Abbott Laboratories, Asahi, Centocor, Inc., ChemoCentryx, Elan Pharmaceuticals, Inc., Ferring, Genentech, Inc., Otsuka, Pharmacia, Protein Design Labs, Procter and Gamble, Prometheus Laboratories, Salix Pharmaceuticals Inc., Shire Pharmaceuticals, Targacept, Therakos, UCB, Inc. | Grant Support | |
| Abbott Laboratories, Centocor, Inc., Ferring, Procter and Gamble, Prometheus, Salix Pharmaceuticals Inc., UCB, Inc. | Honoraria | |
Marla C. Dubinsky |
Elan Pharmaceuticals, Inc., UCB, Inc. |
Advisory Board |
Abbott Laboratories, Prometheus Laboratories, Inc. |
Consultant |
|
| Centocor, Inc., UCB, Inc. | Research Support | |
| Centocor, Inc. | Speakers Bureau | |
Scott E. Plevy |
Abbott Immunology,
Berlex Laboratories,
Callisto Pharmaceuticals,
Celgene Corporation,
Centocor, Inc.,
Dynogen, Inc.,
Elan Pharmaceuticals,
Genentech, Inc.,
Johnson & Johnson,
Otsuka Pharmaceuticals,
Prometheus Laboratories, Inc.
PDL BioPharma, Inc.,
Senesco Technologies, Inc.,
Shire Pharmaceuticals, Sunta Pharmaceuticals, Tanabe Pharmaceuticals, UCB, Inc. |
Advisory Board |
Takeda Pharmaceuticals |
Consultant |
|
| Callisto Pharmaceuticals, Centocor, Inc., Genentech, Inc.,
PDL BioPharma, Inc., Senesco Technologies, Inc., Viamet Pharmaceuticals |
Independent Contractor | |
| Prometheus Laboratories, Inc. | Inventor | |
| Abbott Immunology, Centocor, Inc., Elan Pharmaceuticals, Inc., PDL BioPharma, Inc. | Speaker |
The planners, managers and anyone in a position to control the content of CME activities are also required to report any conflicts of interest. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee.
| Name of Planner or Manager | Company and Relationship |
| Samantha Mattiucci, PharmD, CME Consultants | Nothing to disclose |
| Joyce M. Anderson, Project Director, CME Consultants | Nothing to disclose |
| Sarah Diffen, Senior Project Manager, Strategic Consultants International | Nothing to disclose |
| Alison Howe, Managing Director, Strategic Consultants International | Nothing to disclose |
Certification Statement
CME Consultants, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Consultants designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some of the agents mentioned. Please consult the full prescribing information for full disclosure of approved uses.
Off-label treatments for Crohn’s disease: Certolizumab pegol, natalizumab, AST-120.
This activity should take approximately 90 minutes to complete, including the time to take the post test and complete the evaluation.
This activity was made possible through an educational grant provided by UCB, Inc.
Date of original release: December 12, 2007
Valid for credit through: December 12, 2008